
    
      The study includes 2 treatment periods. The open-label run-in period will begin at patient
      enrolment and continue for 3 weeks, during which all patients will receive once daily
      treatment with zicronapine. The double-blind period will begin at patient randomization and
      continue for 5 weeks, during which the patients will be assigned to one group receiving once
      daily treatment with zicronapine and 3 groups receiving once weekly treatment with
      zicronapine.
    
  